期刊文献+

靶向ANG-2的shRNA重组载体抑制人子宫内膜癌Ishikawa生长和侵袭的研究 被引量:1

Effects of inhibition of ANG-2 expression in Ishikawa cell line
原文传递
导出
摘要 目的探讨采用RNA干扰(RNA interference,RNAi)抑制血管生成素-2(angiopoietin-2,ANG2)基因的表达对人子宫内膜癌细胞Ishikawa细胞的影响。方法采用脂质体Lipofectamine^TM2000介导的方法将针对ANG-2基因的短发卡状RNA(short hairpin RNA,shRNA)表达载体转染到人子宫内膜癌Ishikawa细胞中,逆转录聚合酶链反应及Western印迹法检测ANG-2rnRNA及蛋白的表达;噻唑蓝比色法检测Ishikawa细胞的增殖;荧光显微镜观察细胞形态;流式细胞仪检测细胞周期及凋亡;侵袭实验检测其对侵袭能力的影响。结果人子宫内膜癌Ishikawa细胞ANG-2mRNA及其蛋白质表达水平均显著降低;增殖被抑制,抑制率63.11%;细胞凋亡增加,细胞凋亡率与空白对照组和阴性对照组相比明显增高;细胞生长减慢,阻滞于G1期的增多,S期细胞减少;侵袭能力明显下降。结论靶向ANG-2的shRNA能成功下调ANG-2基因的表达,抑制人子宫内膜癌Ishikawa细胞生长和侵袭。 Objective To investigate the effect of RNA interference mediated angiopoietin-2( ANG- 2 )gene silencing on human endometrial carcinoma cell line ]shikawa. Methods Short hairpin RNA (shRNA) targeting ANG-2 gene was designed and transfected into Ishikawa cells with LipofectamineTM 2000. The mRNA and protein expression level of ANG-2, proliferation, morphological changes, apoptosis, cell cycle and invasive ability of the cells after transfection were analyzed. Results The shRNA targeting the human ANG-2 gene effectively decreased the expression orANG-2 on both mRNA and protein level, the proliferation inhibition rate of the Ishikawa cells was 63.11%, cell apoptosis was induced, and the cell cycle was arrested in G1 phase. The apoptotic rate of the Ishikawa cells in the transfected group was significantly higher, and the invasive ability was decreased markedly, than that of control groups. Conclusion The shRNA targeting human ANG-2 gene could reduce ANG-2 expression, inhibit cellular growth and invasion in Ishikawa cells in vitro.
出处 《中华医学遗传学杂志》 CAS CSCD 北大核心 2009年第3期249-253,共5页 Chinese Journal of Medical Genetics
基金 江苏省社会发展计划研究与发展资助项目(BS2004007)
关键词 RNA干扰 血管生成素-2 子宫内膜癌 ISHIKAWA细胞 基因治疗 RNA interference angiopoietin-2 endometrial carcinoma Ishikawa cells gene therapy
  • 相关文献

参考文献1

二级参考文献10

  • 1Davis S,Aldrich TH,Jones PF,et al.Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning[].Cell.1996
  • 2Suri C,Jones PF,Patan S,et al.Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis[].Cell.1996
  • 3Suri C,McClain J,Thurston G,et al.Increased vascularization in mice overexpressing angiopoietin-1[].Science.1998
  • 4Thurston G,Suri C,Smith K,et al.Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1[].Science.1999
  • 5Maisonpierre PC,Suri C,Jones PF,et al.Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis[].Science.1997
  • 6Holash J,Maisonpierre PC,Compton D,et al.Vessel cooption regression and growth in tumors mediated by angiopoietin and VEGF[].Science.1999
  • 7Lobov IB,Brooks PC,Lang RA.Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo[].Proceedings of the National Academy of Sciences of the United States of America.2002
  • 8Gale N W,Thurston G,Hackett S F,et al.Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1[].Developmental Cell.2002
  • 9Jones N,Iljin K,Dumont D J,et al.Tie receptors: new modulators of angiogenic and lymphangiogenic responses[].Nature Reviews Molecular Cell Biology.2001
  • 10Hu B,Guo P,Fang Q,et al.Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2[].Proceedings of the National Academy of Sciences of the United States of America.2003

共引文献20

同被引文献19

  • 1邓立春,蔡洪川,姜藻,张瑶,沈伟生,袁明,奚蕾.奥沙利铂联合表阿霉素和氟尿嘧啶治疗晚期胃癌的临床观察[J].现代医学,2008,36(4):268-269. 被引量:4
  • 2付莉,朱丹,赵怡璇,李守柔,刘鹏博(编校).拓扑替康和顺铂联合化疗对子宫内膜癌裸鼠移植瘤的抑制作用[J].中国妇幼保健,2007,22(16):2256-2258. 被引量:1
  • 3BOULIKAS T,VOUGIOUKA M.Cisptatin and platinum drugs at the moleeuar level[J].Oncol Rep,2003,10(6):1663.
  • 4MANI S,GRAHAM M A,BREGMAN D B,et al.Oxaliplatin:a review of evolving concepts[J].Cancer Investig,2002,20:246-263.
  • 5LORDICK F,LORENZEN S,STOLLFUSS J,et al.Phase Ⅱ study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as firstline treatment in metastatic gastric cancer[J].Br J Cancer,2005,93(2):190-194.
  • 6MOEHLER M,TEUFEL A,GALLE P R,et al.New chemotherapy strategies in colorectal cancer[J].Recent Results Cancer Res,2005,165:250-259.
  • 7ANEKAANT J,MPHANM A,SANJAY K,et al.Design and develepment of ligand appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer[J].Nanotechnology,Biology,and Medicine,2010,6:179-190.
  • 8AHMAD S A,LIU W,JUNG Y D,et a1.Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma.A possible mechanism for the initiation of angiogenesis[J].Cancer,2001,92:1138-1143.
  • 9SHIMOYAMA S,KAMINISHI M.Angiogenin in sera as an independent prognostic factor in gastric cancer[J].Cancer Res Clin Oncol,2003,129:239-244.
  • 10HISAI H,KATO J,KOBUNE M.Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity[J].Clin Cancer Res,2003,9:4852-2859.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部